BNP Paribas Financial Markets Invests $1.29 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

BNP Paribas Financial Markets bought a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 157,862 shares of the company’s stock, valued at approximately $1,287,000.

Several other hedge funds also recently added to or reduced their stakes in DNA. Wellington Wealth Strategies LLC. purchased a new stake in Ginkgo Bioworks in the 2nd quarter worth approximately $41,000. Benjamin F. Edwards & Company Inc. boosted its holdings in Ginkgo Bioworks by 1,606.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company’s stock worth $79,000 after buying an additional 221,078 shares in the last quarter. PFG Investments LLC acquired a new stake in Ginkgo Bioworks during the third quarter valued at $1,541,000. Algert Global LLC purchased a new position in Ginkgo Bioworks in the second quarter valued at $36,000. Finally, Forbes J M & Co. LLP acquired a new position in shares of Ginkgo Bioworks in the third quarter worth about $1,019,000. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Performance

NYSE:DNA opened at $10.69 on Tuesday. The firm has a 50 day moving average of $8.22. The firm has a market capitalization of $614.46 million, a PE ratio of -0.82 and a beta of 1.17. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.26 and a one year high of $75.20.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DNA. BTIG Research lifted their price target on Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a research note on Friday, August 23rd. TD Cowen upped their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, September 20th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.58.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.